You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Receptor Tyrosine-protein Kinase erbB-2 (HER2) Negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Guangzhou (Take probiotics)

Recruiting
  • Breast Cancer
  • Take probiotics
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

Active, not recruiting
  • Metastatic Cancer
  • HER2 Gene Mutation
  • Neratinib Maleate
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Oct 18, 2023

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer Stage II Trial in Xi'an (Anlotinib)

Recruiting
  • Breast Cancer Stage II
  • Xi'an, Shannxi Province, China
    Xijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)

Terminated
Has Results
  • Breast Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 31, 2022

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,

Active, not recruiting
  • Estrogen Receptor Negative
  • +15 more
  • Bellevue, Nebraska
  • +3 more
Nov 30, 2022

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Older Women With ER Positive, HER2 Negative Early Breast Cancer

Enrolling by invitation
  • Breast Cancer Female
  • Translational study
  • Sutton, United Kingdom
    The Royal Marsden NHS Foundation Trust
Feb 8, 2023

Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jan 30, 2023

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

Recruiting
  • Breast Cancer
  • Saint Louis, Missouri
  • +2 more
Jan 12, 2023